Supplements and Compounds Library
Every article, presentation, spotlight, and news item we've tagged to Supplements and Compounds.
Showing 49–72 of 328
As obesity drugs go oral and access grows, so do fakes
The transition from injectable GLP-1 drugs to oral formulations is expanding patient access and treatment options, but creates new vulnerabilities to counterfeit products that pose direct safety risks. Regulatory vigilance and supply chain authentication will be critical as the weight-loss drug market scales to an estimated $100 billion by 2030.
Dual GLP-1/Glucagon Agonist Reaches Peak Doses in Obesity Trial
MetaVia's Phase 1 trial of DA-1726, a dual GLP-1/glucagon receptor agonist, has achieved dose titration milestones at 48 mg and 64 mg in obese adults. The trial structure evaluates safety, tolerability, and metabolic effects across escalation strategies, with topline results expected in Q4 2026.
Lean mass preservation during GLP-1 therapy reshapes obesity treatment
Noom has launched a free GLP-1 Companion program to address a critical gap in obesity treatment: sustaining weight loss and preserving lean mass after the initial pharmacological response. The shift reflects growing recognition that weight loss durability and body composition outcomes—not weight reduction alone—determine metabolic health and longevity.
Advancing senescence translation through the Senotherapeutics Biomarker Consortium
The Senotherapeutics Biomarker Consortium establishes standardized biomarkers for identifying and measuring cellular senescence across tissues and populations, enabling translation of senolytic therapies from research to clinical practice. This addresses a critical gap in longevity medicine: the ability to reliably detect senescent cells and track treatment response in living humans.
Targeting Mitochondrial Stress Responses: Terbinafine and Miglustat as Novel Lifespan and Healthspan Modulators
Terbinafine and miglustat, FDA-approved drugs, extend lifespan and healthspan by inducing mitochondrial stress responses through coordinated activation of ATFS-1 and DAF-16 pathways. This mechanism represents a distinct integration of mitochondrial and insulin signaling stress responses relevant to aging intervention.
Weight returns fast after quitting GLP-1 drugs, study and experts say
Weight loss achieved through GLP-1 medications returns rapidly after discontinuation—approximately one pound per month, with most patients regaining initial weight within two years. This rebound occurs nearly four times faster than weight regain following diet or exercise cessation, underscoring that pharmacological intervention without sustained lifestyle modification produces temporary rather than durable health outcomes.
GLP-1 Success Depends on Daily Behavior, Not Scale Weight
A collaboration between Ōura and LillyDirect signals a fundamental shift in how GLP-1 therapies are deployed clinically — moving beyond single-intervention prescribing toward integrated care that combines pharmacotherapy with real-time biometric tracking and behavioral support. This model reframes health outcomes as the cumulative product of daily decisions rather than point-in-time measurements, suggesting that sustained metabolic health requires continuous signal interpretation across sleep, activity, recovery, and stress patterns.
Allergan Aesthetics finds its next growth engine in GLP-1s
GLP-1 weight-loss medications are creating a new patient population in aesthetic medicine, with 52% of GLP-1-treated patients expressing concerns about facial appearance changes and 32% being new to aesthetic practices. This represents market expansion rather than simple demand shifting, driven by patients seeking natural-looking, lower-commitment interventions to address facial volume loss during weight loss.
DNA Methylation Signatures of Cellular Senescence Are Not Reversed by Senolytic Treatment
Senolytic treatments did not reverse epigenetic signatures associated with cellular senescence, despite reducing senescent cell burden. This finding questions whether DNA methylation changes adequately capture senescence biology and whether current aging biomarkers respond as expected to geroscience interventions.
MetaVia to present high-dose obesity drug data at major liver congress
MetaVia will present Phase 1 safety and pharmacokinetic data for DA-1726, a once-weekly GLP-1/glucagon dual agonist, at the European Association for the Study of the Liver Congress in May 2026. Preclinical evidence suggests potential advantages over existing weight-loss agents in weight reduction, glucose control, and lean mass preservation, with particular relevance to metabolic dysfunction-associated liver disease.
Metformin Cancer Risk: Why One-Size Dosing Fails
Metformin's cancer risk profile remains inconsistent across tumor types, with prostate cancer showing increased incidence in some populations while other malignancies show protective associations. This heterogeneity demands precision in how the drug is prescribed for metabolic optimization, as blanket recommendations obscure the mechanistic and epidemiological distinctions between different cancer contexts.
A Popular Senolytic Treatment Causes Brain Damage in Mice
Dasatinib and quercetin (D+Q), a widely used senolytic combination, impairs oligodendrocyte function and reduces myelination in the brain through endoplasmic reticulum stress, causing morphological changes similar to those seen in multiple sclerosis. This finding indicates that senolytic interventions carry neurological risks that warrant careful evaluation before clinical deployment.
NR Supplements Reduce Muscle Epigenetic Aging; HIIT Shows Mixed Results
Nicotinamide riboside supplementation reduced epigenetic age acceleration in skeletal muscle over five months, while high-intensity interval training produced divergent effects depending on the measurement method used. Changes in mitochondrial content correlated with epigenetic aging shifts, suggesting mitochondrial function as a mechanistic link between these interventions and cellular aging markers.
Magnesium dosing by function plus measurement
Decode Age, an Indian longevity company, converted a $1.7 million funding round into tangible product launches and diagnostic expansion within eight months, including a multi-form magnesium supplement and planned microbiome testing. The company's strategy centers on pairing supplementation with biomarker measurement to create accountability for intervention efficacy at the biological level.
Senolytic Treatment Reduces Acute and Chronic Lung Inflammation in an Aged Mouse Model of Influenza
Senolytic treatment with ABT-263 reduced lung and intestinal inflammation and prevented long-term pulmonary damage in aged mice infected with influenza, though it did not reduce viral replication itself. The findings indicate that pre-existing senescent cells drive inflammatory pathology rather than viral control, suggesting a therapeutic target for improving outcomes in older adults.
Gubra-AbbVie obesity drug nears 10% weight loss
ABBV-295, an amylin-mimetic therapy from Gubra and AbbVie, produced 7.75–9.79% weight loss over 12 weeks in Phase 1 trials with a favorable safety profile. The drug targets a distinct hormonal pathway from current GLP-1 therapies, offering potential for multi-signal appetite regulation and sustained metabolic improvement.
GLP-1 drug enters trial for progressive multiple sclerosis
A long-acting GLP-1 receptor agonist has entered Phase 2 trials for progressive multiple sclerosis, marking a shift in how researchers view this drug class beyond metabolic disease. The compound targets neuroinflammation and neurodegeneration rather than immune suppression alone, addressing a core limitation of existing MS therapies.
Myostatin inhibitors preserve muscle mass during GLP-1 weight loss
NorthStrive Biosciences has filed patent applications for two therapeutic candidates designed to preserve lean muscle mass during GLP-1-mediated weight loss and other catabolic states. The compounds target myostatin and activin A pathways through peptide and probiotic delivery mechanisms, addressing a significant gap in current obesity pharmacotherapy where muscle loss accompanies fat loss.
Three drugs in major study to prove their capacity to slow aging
UT Health San Antonio is launching VITAL-H, a $38 million clinical trial enrolling over 700 adults to test whether three existing drugs—rapamycin, semaglutide, and dapagliflozin—can slow biological aging in humans. This represents the first large-scale human trial specifically designed to evaluate pharmaceutical intervention in aging processes.
Thymulin Restores Immune Function in Aging Cancer Models
Thymulin, a hormone produced by the thymus gland, reduces systemic inflammation in aging mice and enhances the effectiveness of cancer treatments. The research identifies thymulin as a circulating factor capable of modulating age-related immune dysfunction independently of full immune system rejuvenation.
New COSRX peptide serum taps growing skin longevity market
COSRX's Blue Peptide Bakuchiol serum addresses emerging consumer demand for skin resilience and long-term health rather than antiaging reversal, specifically acknowledging how body composition changes—including from GLP-1 medications—affect facial firmness and elasticity. The product democratizes peptide-based skincare by making copper tripeptide-1 accessible at mid-market price points rather than luxury positioning.
$30.8m funds Cambrian Bio’s bid to preserve resilience in aging
Cambrian Bio received $30.8 million in ARPA-H funding to test whether a selective mTORC1 inhibitor can preserve intrinsic capacity—the physical and metabolic resilience that maintains function during aging—before disease manifests. This represents a fundamental shift from treating established disease to intervening in the aging process itself, with success measured through a composite biomarker framework rather than disease endpoints.
Rubedo: the senolytic alchemist of aging biology
Rubedo Life Sciences has advanced RLS-1496, a first-in-class GPX4 modulator senolytic, through Phase 1 human trials based on the company's ALEMBIC AI platform for identifying senescent cell vulnerabilities. This represents a shift from repurposed compounds toward precision-targeted senolytics designed to eliminate dysfunctional cells while sparing healthy tissue.
Resveratrol delivery breakthrough targets Parkinson's cell aging
Jupiter Neurosciences has initiated Phase 2a enrollment for JOTROL, an oral resveratrol derivative designed to address underlying neurodegeneration in Parkinson's disease rather than manage symptoms alone. The formulation achieves nine-fold higher bioavailability than standard resveratrol and demonstrated measurable central nervous system penetration, potentially addressing the chronic inflammation and mitochondrial dysfunction that drive disease progression.